[{"text": "Bupropion and cognitive-behavioral therapy for smoking cessation in women", "labels": [], "entities": []}, {"text": "Gender data for bupropion suggest that it maybe a particularly effective smoking cessation medication for women.", "labels": [], "entities": []}, {"text": "It is not known whether the efficacy of this pharmacotherapy differs as a function of the psychotherapy with which it is administered.", "labels": [], "entities": []}, {"text": "This study used a two level factorial design to examine the independent and interactive effects of medication (bupropion 300 mg/day vs. placebo) and psychotherapy (cognitive-behavioral therapy [CBT] vs. supportive therapy [ST]).", "labels": [], "entities": []}, {"text": "In addition to testing the hypothesis that bupropion with CBT would be most effective of all the treatments, we examined medication compliance and its role in the efficacy of bupropion.", "labels": [], "entities": []}, {"text": "Participants were 154 women, aged at least 30 years and smoking more than 10 cigarettes/day.", "labels": [], "entities": []}, {"text": "Compliance with study medication was assessed using Medication Event Monitoring Systems (MEMS) over 7 weeks of treatment.", "labels": [], "entities": []}, {"text": "Psychological interventions were delivered in 60 - min weekly group sessions.", "labels": [], "entities": [{"text": "group sessions.", "start_pos": 62, "end_pos": 77, "type": "Face_to_face", "confidence": 0.5904027918974558}]}, {"text": "Longitudinal analysis of abstinence outcomes from end of treatment (EOT) through 12 months after treatment revealed a significant interaction of medication and therapy.", "labels": [], "entities": []}, {"text": "Higher abstinence rates at EOT and 3-, 6-, 9-, and 12 - month follow-ups were observed when bupropion was delivered concurrently with CBT (44%, 24%, 30%, 23%, 17%) rather than with ST (18%, 1%, 8%, 5%, 2%).", "labels": [], "entities": [{"text": "12", "start_pos": 51, "end_pos": 53, "type": "Longest_follow_up", "confidence": 0.9470499753952026}]}, {"text": "The bupropion-CBT combination, however, was not clearly superior to placebo, regardless of therapy assignment.", "labels": [], "entities": []}, {"text": "Higher rates of medication compliance were positively predictive of abstinence, and this effect was most evident in the placebo condition.", "labels": [], "entities": []}, {"text": "Findings provide only modest support for CBT as the preferred type of intensive therapy in conjunction with bupropion in women.", "labels": [], "entities": []}, {"text": "Pharmacotherapy with counseling or behavioral therapy is the recommended treatment for tobacco dependence ().", "labels": [], "entities": []}, {"text": "Along with nicotine replacement therapies (NRTs), there now exists a consistent body of scientific evidence supporting the safety and efficacy of bupropion for smoking cessation.", "labels": [], "entities": []}, {"text": "Data pooled from 12 randomized clinical trials showed that, for both women and men, bupropion more than doubled the odds of a successful outcome, compared with placebo ().", "labels": [], "entities": []}, {"text": "In addition, clinical studies have extended the efficacy of bupropion to special populations, including smokers with a history of alcoholism or depression (), schizophrenia (), chronic posttraumatic stress disorder), cardiovascular disease (, chronic obstructive pulmonary disease (), previous failure with bupropion (), and recent abstinence from smoking (.", "labels": [], "entities": []}, {"text": "Bupropion also has shown efficacy in ethnic minority groups, including African American smokers) and heavy smokers of Mexican descent.", "labels": [], "entities": []}, {"text": "Women, like men, are more than twice as likely to quit successfully with bupropion, compared with placebo ().", "labels": [], "entities": []}, {"text": "Compared with men, however, women have significantly lower success rates, regardless of whether they receive treatment with bupropion or placebo.", "labels": [], "entities": [{"text": "bupropion", "start_pos": 124, "end_pos": 133, "type": "Pill", "confidence": 0.8943265080451965}]}, {"text": "It is puzzling that bupropion, with its purported pharmacological actions on mechanisms related to negative affect, depression, and weight gain, is not more effective for women.", "labels": [], "entities": []}, {"text": "It seems that for women, response to pharmacotherapy may improve with intensity of nonpharmacological support or counseling during cessation.", "labels": [], "entities": []}, {"text": "In the case of NRT, recent meta-analysis results support the notion that giving NRT in conjunction with high-intensity nonpharmacological treatment is more important for women than men.", "labels": [], "entities": []}, {"text": "In an effectiveness trial of bupropion in combination with higher-or lower-intensity counseling , gender-specific analyses showed that, for women, participation in more intensive proactive telephone counseling reduced the likelihood of smoking at 12 - month follow-up compared with participation in the less-intensive, tailored-mail program.", "labels": [], "entities": []}, {"text": "To our knowledge, no studies have examined response to bupropion in women when medication is delivered in conjunction with different types of intensive clinic-based interventions.", "labels": [], "entities": []}, {"text": "To the extent that, for women, smoking-associated cues play a more important role than nicotine per se in controlling smoking behavior), it follows that cognitive-behavioral therapy (CBT) that focuses on identifying and managing triggers would be particularly well-suited for this subpopulation of smokers.", "labels": [], "entities": []}, {"text": "In the majority of randomized clinical trials to date, however, bupropion has been delivered on a platform of ''standard'' or ''behavioral'' counseling (e.g.,), typically brief in duration, with abroad agenda of topics.", "labels": [], "entities": []}, {"text": "Thus the specific effects of CBT in conjunction with bupropion are unknown.", "labels": [], "entities": []}, {"text": "The present study compared CBT with supportive therapy (ST)-a more general, yet intensive approach-in a sample of women smokers.", "labels": [], "entities": [{"text": "ST", "start_pos": 56, "end_pos": 58, "type": "Arm_name", "confidence": 0.8641076683998108}]}, {"text": "In pharmacotherapy trials, including bupropion treatment in women, medication compliance is likely a source of heterogeneity in outcome.", "labels": [], "entities": []}, {"text": "Ina subgroup analysis of women receiving bupropion, Swan, Javitz, Jack, Curry, and found the highest rates of successful smoking cessation in women high in adherence, taking their medication on 50.4 of the 56 total prescribed days (90%).", "labels": [], "entities": []}, {"text": "We reported a similar positive relationship between compliance level and abstinence status during an open-label trial of bupropion in a sample of women, all of whom were given an electronic pill-dispensing device (Medication Event Monitoring Systems) to record bottle openings indicating pilltaking behavior.", "labels": [], "entities": []}, {"text": "At 3 and 6 weeks, women with higher levels of compliance were more likely to be abstinent).", "labels": [], "entities": []}, {"text": "Together, these observations suggest that responsiveness to bupropion maybe enhanced by compliance, which, if unaccounted for, could bias assessment of pharmacotherapy effectiveness.", "labels": [], "entities": []}, {"text": "To summarize, the primary objective of this clinical trial was to better characterize the efficacy of bupropion for women specifically.", "labels": [], "entities": []}, {"text": "A two level factorial model was used in which medication (bupropion 300 mg/day vs. placebo) was crossed with psychotherapy (CBT vs. ST).", "labels": [], "entities": []}, {"text": "We predicted that (a) bupropion would produce higher abstinence rates than placebo, (b) the effects of bupropion would be greater when combined with CBT, and (c) medication compliance would improve the efficacy of bupropion.", "labels": [], "entities": []}, {"text": "Secondary analyses examined the effect of treatment condition on other outcomes of interest, including tobacco consumption (cigarettes/day), craving, withdrawal, body weight, and side effects.", "labels": [], "entities": []}, {"text": "This study was conducted at the outpatient Treatment Research Clinic (TRC), a component of the Department of Psychiatry and Behavioral Sciences Substance Abuse Research Center, located in the University of Texas Medical Center at Houston.", "labels": [], "entities": [{"text": "Texas", "start_pos": 206, "end_pos": 211, "type": "Lower-level_geographical_region", "confidence": 0.9600147604942322}, {"text": "Houston", "start_pos": 230, "end_pos": 237, "type": "Lower-level_geographical_region", "confidence": 0.9654190540313721}]}, {"text": "Women eligible for participation were required to be aged 30 - 70 years, smoke at least 10 cigarettes/day, be in generally good health, and rate themselves as ''motivated'' to quit smoking (>5 on an eight-point rating scale).", "labels": [], "entities": []}, {"text": "Exclusion criteria included a history of seizure disorder, severe head trauma, anorexia nervosa, or bulimia; presence of a current psychiatric disorder or serious medical condition; pregnancy or breastfeeding; dependence on alcohol or other illicit substances; or concurrent drug therapy or psychotherapy for smoking cessation.", "labels": [], "entities": []}, {"text": "Participants were recruited by local radio, television, and print ads fora smoking cessation treatment study.", "labels": [], "entities": []}, {"text": "A total of 231 women participated in an initial screening interview; 189 met screening criteria and were invited to attend an intake assessment visit at the TRC.", "labels": [], "entities": [{"text": "231", "start_pos": 11, "end_pos": 14, "type": "Individual-level_allocated", "confidence": 0.48869404196739197}, {"text": "women", "start_pos": 15, "end_pos": 20, "type": "All_female", "confidence": 0.8050362467765808}]}, {"text": "At this visit, the study was explained, written informed consent was obtained, and baseline assessments were completed.", "labels": [], "entities": []}, {"text": "The final sample of participants completing intake assessment and fulfilling all eligibility criteria (N5154) were randomly assigned to one of the four treatment groups using an urn procedure, balancing conditions on baseline variables shown previously to be related to outcome, including depressive symptoms, self-efficacy, and longest past abstinence (.", "labels": [], "entities": []}, {"text": "All study procedures, the consent form, and advertisements were reviewed and approved by the University of Texas Committee for the Protection of Human Subjects.", "labels": [], "entities": []}, {"text": "Investigators and research staff were blind to the randomization codes, which were kept by a faculty member independent of the research and treatment team.", "labels": [], "entities": [{"text": "research staff", "start_pos": 18, "end_pos": 32, "type": "Researcher_not_otherwise_specified", "confidence": 0.5805259943008423}]}, {"text": "Immediately after randomization, the study nurse conducted an orientation session with each participant to review the pharmacotherapy regimen and administer the first dose of the assigned study medication.", "labels": [], "entities": []}, {"text": "Sustained-release bupropion (300 mg/day; 150 mg/day for 3 days, followed by 150 mg twice daily) or matching unmarked placebo tablets were packaged in MEMS by the pharmacist and dispensed weekly by the nurse in double-blind fashion.", "labels": [], "entities": []}, {"text": "Participants were told to take one tablet (150 mg) in the morning and one tablet (150 mg) in the evening with at least 8 hours, but not more than 12 hours, between doses.", "labels": [], "entities": []}, {"text": "Medications were provided by GlaxoSmithKline.", "labels": [], "entities": []}, {"text": "All participants received weekly, 60 - min sessions of group therapy over 7 weeks.", "labels": [], "entities": [{"text": "group", "start_pos": 55, "end_pos": 60, "type": "Group-based", "confidence": 0.8659663200378418}]}, {"text": "The target quit day (TQD) was set for the morning of the first session, 10 days after the start of medication.", "labels": [], "entities": [{"text": "target quit day", "start_pos": 4, "end_pos": 19, "type": "1.1.Goal_setting_(behavior)", "confidence": 0.7965282599131266}]}, {"text": "Group therapy sessions were conducted by a therapist and cotherapist pair.", "labels": [], "entities": [{"text": "therapist", "start_pos": 43, "end_pos": 52, "type": "Psychologist", "confidence": 0.6106007099151611}]}, {"text": "Four female, master's-level therapists were trained on each therapy manual and supervised weekly by a doctoral-level clinical psychologist.", "labels": [], "entities": [{"text": "therapists", "start_pos": 28, "end_pos": 38, "type": "Psychologist", "confidence": 0.5072954297065735}, {"text": "trained on each therapy manual", "start_pos": 44, "end_pos": 74, "type": "Expertise_of_Source", "confidence": 0.8194339275360107}]}, {"text": "In addition, weekly sessions were videotaped and reviewed for therapy adherence.", "labels": [], "entities": []}, {"text": "Evidence of deviation from the specified manual was discussed and corrective steps taken.", "labels": [], "entities": []}, {"text": "Randomly selected videotapes were rated by independent staff blind to the therapy type.", "labels": [], "entities": []}, {"text": "Raters listened to assigned tapes and classified each according to adherence rating scales consisting of core elements prescribed and proscribed in the therapy manuals.", "labels": [], "entities": []}, {"text": "As shown in, this integrity check provided good evidence of therapist fidelity to the manual-based protocols.", "labels": [], "entities": []}, {"text": "CBT was based on Marlatt and Gordon's (1985) relapse prevention model and adapted for use with cigarette smokers.", "labels": [], "entities": []}, {"text": "Therapists provided a model of smoking as a learned addiction and CBT as the process of ''unlearning'' the tobacco habit through coping skills acquisition.", "labels": [], "entities": [{"text": "Therapists", "start_pos": 0, "end_pos": 10, "type": "Psychologist", "confidence": 0.5353308916091919}]}, {"text": "The CBT manual) provided skills-training techniques for managing relapse-related thoughts and behaviors.", "labels": [], "entities": []}, {"text": "Key topics included identification of smoking triggers, functional analysis, handling of lapses, lifestyle balancing, and problem solving.", "labels": [], "entities": []}, {"text": "The therapy style was active and directive, with role playing used regularly as a training technique.", "labels": [], "entities": []}, {"text": "Between-session practice assignments were reviewed at the subsequent session.", "labels": [], "entities": []}, {"text": "ST was designed to enhance the provision and receipt of social support during smoking cessation.", "labels": [], "entities": [{"text": "social support during smoking cessation.", "start_pos": 56, "end_pos": 96, "type": "3.1_Social_support_(unspecified)", "confidence": 0.8062173922856649}]}, {"text": "The relationship between level of support and the likelihood of successful smoking cessation was explained as the therapy rationale.", "labels": [], "entities": []}, {"text": "The goal of ST was to instill group support and encouragement of cessation efforts.", "labels": [], "entities": [{"text": "instill group support and encouragement of cessation efforts.", "start_pos": 22, "end_pos": 83, "type": "3.1_Social_support_(unspecified)", "confidence": 0.692869656615787}]}, {"text": "Using a nondirective style, therapists facilitated group discussion around topics related to quitting in general.", "labels": [], "entities": [{"text": "therapists", "start_pos": 28, "end_pos": 38, "type": "Psychologist", "confidence": 0.670504629611969}]}, {"text": "Participants were encouraged to share and discuss aspects of their smoking cessation experiences and give feedback to other group members.", "labels": [], "entities": []}, {"text": "Therapists refrained from using skills-training techniques or giving direct advice.", "labels": [], "entities": [{"text": "Therapists", "start_pos": 0, "end_pos": 10, "type": "Psychologist", "confidence": 0.5109503865242004}]}, {"text": "Home practice assignments and self-monitoring were not allowed.", "labels": [], "entities": []}, {"text": "The therapist manual was an adaptation of a health belief intervention described in detail elsewhere ().", "labels": [], "entities": [{"text": "therapist", "start_pos": 4, "end_pos": 13, "type": "Psychologist", "confidence": 0.58172208070755}]}, {"text": "Intake assessment included a medical history, physical examination, psychiatric screening (SCID; First, Spitzer,, and a brief interview to collect information regarding demographics and smoking behavior.", "labels": [], "entities": []}, {"text": "Other measures completed at intake included the Fagerstr\u00f6 m Test for Nicotine Dependence (FTND; Heatherton,, the Beck Depression Inventory (BDI; Beck,, the Smoking Confidence Questionnaire (SCQ;, and the Questionnaire on Smoking Urges (QSU;.", "labels": [], "entities": []}, {"text": "During the study, participants completed daily smoking diaries to record smoking behavior.", "labels": [], "entities": [{"text": "daily smoking diaries to record smoking behavior.", "start_pos": 41, "end_pos": 90, "type": "2.3_Self-monitoring_of_behavior", "confidence": 0.7793476358056068}]}, {"text": "These data were collected at each treatment visit by the research assistant, who also downloaded MEMS data and recorded adverse events, concomitant medication use, withdrawal symptoms, vital signs (i.e., weight, pulse, resting blood pressure), and expired carbon monoxide (CO) levels.", "labels": [], "entities": [{"text": "expired carbon monoxide (CO)", "start_pos": 248, "end_pos": 276, "type": "Biochemical_verification", "confidence": 0.8069217006365458}]}, {"text": "The QSU was completed at each weekly clinic visit.", "labels": [], "entities": []}, {"text": "From the randomized sample, 59 participants did not provide compliance data and were classified as nonevaluable for this analysis.", "labels": [], "entities": [{"text": "59", "start_pos": 28, "end_pos": 30, "type": "Individual-level_analysed", "confidence": 0.5413955450057983}]}, {"text": "This subsample included 14 participants who never started treatment and 45 participants who dropped out of treatment early or never used or returned the MEMS bottles.", "labels": [], "entities": []}, {"text": "We compared the groups (evaluable vs. nonevaluable) on a number of baseline demographic and smoking history variables and found no significant differences.", "labels": [], "entities": []}, {"text": "Among the evaluable group, average compliance levels during treatment were the same for bupropion (47%) and placebo (45%), t(82)50.34, p50.57.", "labels": [], "entities": []}, {"text": "The effect of compliance on abstinence at EOT is presented in.", "labels": [], "entities": []}, {"text": "We found a significant medication effect, favoring bupropion, x 2 56.41, df51, p50.011, as well as a significant effect of compliance, x 2 57.87, df51, p50.005, favoring higher levels of compliance.", "labels": [], "entities": []}, {"text": "The interaction between medication and compliance was significant, x 2 56.50, df51, p50.010, indicating that rates of abstinence differed between the placebo and bupropion groups as a function of compliance.", "labels": [], "entities": []}, {"text": "As shown in, among participants receiving placebo, those with higher compliance were more likely to be abstinent at EOT.", "labels": [], "entities": []}, {"text": "For participants receiving bupropion, compliance levels did not predict abstinence rates at EOT.", "labels": [], "entities": []}, {"text": "Biochemically confirmed 7 - day point-prevalence abstinence was used to classify smoking status (.", "labels": [], "entities": [{"text": "smoking", "start_pos": 81, "end_pos": 88, "type": "Smoking", "confidence": 0.8143401741981506}]}, {"text": "During treatment, abstinence was determined at each clinic visit by self-report of no smoking in the past 7 days and a CO level of no more than 10 ppm).", "labels": [], "entities": [{"text": "CO level", "start_pos": 119, "end_pos": 127, "type": "Biochemical_verification", "confidence": 0.8093628287315369}]}, {"text": "During followup, self-reported abstinence during the preceding 7 days was verified by CO analysis and a salivary cotinine level of less than 15 ng/ml).", "labels": [], "entities": [{"text": "CO analysis", "start_pos": 86, "end_pos": 97, "type": "Biochemical_verification", "confidence": 0.8984217345714569}, {"text": "salivary cotinine", "start_pos": 104, "end_pos": 121, "type": "Biochemical_verification", "confidence": 0.8993754088878632}]}, {"text": "Salivary cotinine samples were analyzed by ABS Laboratories (London, England).", "labels": [], "entities": [{"text": "Salivary cotinine samples", "start_pos": 0, "end_pos": 25, "type": "Biochemical_verification", "confidence": 0.7697329918543497}]}, {"text": "The planned sample size was based on standard assumptions (i.e., a50.05, b50.80) and available data at the time of study design suggesting medium effect sizes for both medication and therapy differences).", "labels": [], "entities": []}, {"text": "Power levels in the final intention-to-treat sample size (N5154) were sufficient for exploratory but not confirmatory analysis of hypothesized interaction effects.", "labels": [], "entities": []}, {"text": "All analyses were conducted using SAS version 9.1.", "labels": [], "entities": []}, {"text": "Unless stated otherwise, p values of less than 0.05 were considered statistically significant, based on two-tailed tests.", "labels": [], "entities": []}, {"text": "Effect sizes and 95% confidence intervals were computed using a specialized SAS routine written by.", "labels": [], "entities": []}, {"text": "Analysis of variance and chi-square tests were used to evaluate baseline differences among treatment groups.", "labels": [], "entities": []}, {"text": "Treatment retention was compared using Kaplan-Meier survival analysis.", "labels": [], "entities": []}, {"text": "The study design included two design variables (medication6psychotherapy) and time (week 1 [TQD], week 7 [EOT], 3-, 6-, 9-, and 12 - month follow-up) as the repeated within-subject variable.", "labels": [], "entities": [{"text": "12", "start_pos": 128, "end_pos": 130, "type": "Longest_follow_up", "confidence": 0.9703807830810547}]}, {"text": "The primary outcome variable, point-prevalence abstinence, was analyzed using generalized linear mixed models (GLMM;) with missing data omitted from the model).", "labels": [], "entities": []}, {"text": "To account for the hierarchical study design of medication condition clustered within therapy condition, therapy group number (i.e., 1 through 29) was treated as a random effect.", "labels": [], "entities": []}, {"text": "GLMM models were tested using the MIXED procedure with the GLIMMIX macro to handle nonnormally distributed dichotomous data ().", "labels": [], "entities": []}, {"text": "Reanalysis of primary outcome data with missing coded as smoking was conducted to test missing data assumptions and robustness of the results ().", "labels": [], "entities": []}, {"text": "To evaluate the role of medication compliance in relation to the efficacy of bupropion, we used logistic regression to model EOT abstinence status as the outcome, with overall compliance score (0 - 1.0), medication group (bupropion vs. placebo), and the compliance6medication interaction terms as predictors.", "labels": [], "entities": []}, {"text": "Known correlates of treatment response were entered as covariates, including age, longest previous abstinence, FTND score, SCQ score, treatment expectancy score, and changes in nicotine withdrawal and craving from baseline to TQD (cf., Jackson, Stapleton,.", "labels": [], "entities": []}, {"text": "For secondary outcome variables, including smoking rate (cigarettes/day), craving, withdrawal, body weight, and side effects, GLMM analyses were conducted on weekly measurements during treatment with baseline scores included as covariate terms.", "labels": [], "entities": [{"text": "smoking", "start_pos": 43, "end_pos": 50, "type": "Smoking", "confidence": 0.7102512717247009}]}, {"text": "Smoking rate was analyzed using Poisson regression under the GENMOD procedure.", "labels": [], "entities": [{"text": "Smoking", "start_pos": 0, "end_pos": 7, "type": "Smoking", "confidence": 0.5406831502914429}]}, {"text": "To evaluate the effect of smoking status on these secondary outcomes, point-prevalence abstinence was included as a dynamic covariate in complementary analyses.", "labels": [], "entities": []}, {"text": "Because the fixed-effect estimates were unchanged in these analyses, results presented here are based on analyses that are covariate-adjusted for baseline scores only.", "labels": [], "entities": []}, {"text": "As shown in, the ethnic composition of the sample of 154 participants randomized to treatment was 70.1% White, 25.3% Black, and 4.6% Hispanic.", "labels": [], "entities": [{"text": "154", "start_pos": 53, "end_pos": 56, "type": "Individual-level_analysed", "confidence": 0.5802565217018127}, {"text": "70.1", "start_pos": 98, "end_pos": 102, "type": "Proportion_identifying_as_female_gender", "confidence": 0.3398876488208771}]}, {"text": "Most were unmarried (59.8%), employed (65.0%), with a mean age of 47.8 years (SD59.3) and approximately 14.3 years of education (SD52.4).", "labels": [], "entities": [{"text": "47.8", "start_pos": 66, "end_pos": 70, "type": "Mean_age", "confidence": 0.9863683581352234}]}, {"text": "Regarding smoking history, the baseline rate of daily smoking was 21.4 cigarettes/day (SD59.1) with a mean FTND score of 5.8 (SD52.3).", "labels": [], "entities": [{"text": "21.4", "start_pos": 66, "end_pos": 70, "type": "Mean_number_of_times_tobacco_used", "confidence": 0.8911261558532715}]}, {"text": "Most subjects (86.3%) had made at least one previous attempt to stop smoking.", "labels": [], "entities": []}, {"text": "A total of 18% of the participants reported a history of depression, and 15% reported prior bupropion use.", "labels": [], "entities": []}, {"text": "We found no significant differences between groups on these baseline variables.", "labels": [], "entities": []}, {"text": "Of the 154 participants randomized, 14 did not enter treatment due to emergent medical conditions unreported at intake (n52), unforeseen family or employment conflicts (n59), and failure to return to the clinic (n53).", "labels": [], "entities": []}, {"text": "Of the 140 participants who began treatment, 81 (57.9%) remained in treatment and attended an average of 4.4 (SD52.8) sessions.", "labels": [], "entities": []}, {"text": "A comparison of participants who remained in treatment (n581) with those who dropped out (n573) revealed no significant differences on any of the demographic or baseline variables, with the exception of baseline weight (M5155.4 pounds, SD528.7 vs. M5171.2 pounds, SD540.7, respectively, t[124]52.37, p50.0194.", "labels": [], "entities": []}, {"text": "Overall, the median time to dropout was 4 weeks.", "labels": [], "entities": []}, {"text": "We found no significant differences between treatment groups in the distribution of time to dropout (log rank statistic53.13, df53, p50.3720).", "labels": [], "entities": []}, {"text": "Of the 59 participants who did not complete treatment, 24 (40.7%) were successfully tracked and assessed for abstinence during follow-up on at least one occasion.", "labels": [], "entities": []}, {"text": "We were unable to contact the remaining 35 treatment dropouts, despite extensive efforts to track these individuals.", "labels": [], "entities": []}, {"text": "These 35 individuals did not differ significantly from the 24 treatment dropouts we reached on a range of baseline and treatment variables.", "labels": [], "entities": []}, {"text": "One exception was a slightly greater FTND score for those not followed up (6.7 vs. 5.6, p,0.05).", "labels": [], "entities": []}, {"text": "Thus the percentages of complete outcome data collected at 3, 6, 9, and 12 months were 49.2%, 45.7%, 49.2%, and 50.0%, respectively.", "labels": [], "entities": []}, {"text": "Point-prevalence abstinence rates for each treatment group at each assessment time point are displayed in.", "labels": [], "entities": []}, {"text": "GLMM analyses revealed no main effects for medication, therapy, or time.", "labels": [], "entities": []}, {"text": "A significant medication6therapy interaction was found, F(1, 98.3)54.38, p50.0389, R 2 50.04, 95% CI50.00 - 0.14, however, revealing differences in abstinence rates between CBT and ST as a function of medication condition (see).", "labels": [], "entities": []}, {"text": "For bupropion-treated participants, abstinence rates averaged across time were higher when the medication was delivered with CBT rather than ST.", "labels": [], "entities": []}, {"text": "BDI5Beck Depression Inventory-I (; FTND5Fagerstr\u00f6 m Test for Nicotine Dependence (.", "labels": [], "entities": []}, {"text": "Continuous measures were analyzed using ANOVA and reported as means and standard deviations.", "labels": [], "entities": []}, {"text": "Categorical measures were analyzed with chi-square tests.", "labels": [], "entities": []}, {"text": "a Previous quit attempts, longest quit, and cotinine were positively skewed and were transformed as follows prior to analysis-log 10 (quit attempts + 1, longest quit + 1) and log 10 (total plasma cotinine)-and then transformed back to original for ease of interpretation.", "labels": [], "entities": []}, {"text": "receiving placebo, averaged abstinence rates favored the groups receiving concurrent ST.", "labels": [], "entities": []}, {"text": "Reanalysis with missing data coded as smoking produced the same medication6therapy interaction patterns.", "labels": [], "entities": []}, {"text": "During the treatment phase, bupropion resulted in significantly lower rates of daily smoking (M53.25 cigarettes/day) compared with placebo (M55.35 cigarettes/day), x 2 54.65, df51, p50.0311.", "labels": [], "entities": []}, {"text": "A time effect was found, x 2 515.59, df56, p50.0161, showing slight but significant (p,0.05) fluctuations between several weeks of treatment (i.e., decline from week 1 to week 2, increase from week 2 to week 3, increase from week 6 to week 7).", "labels": [], "entities": []}, {"text": "Changes in craving during treatment were evaluated separately for the two factors of the QSU.", "labels": [], "entities": []}, {"text": "For factor 1, anticipated pleasure from smoking, F(6, 73)513.00, p,0.0001, and Factor 2, anticipated withdrawal relief, F(6, 73.5)59.00, p,0.0001, time effects showed elevated craving scores prior to TQD, returning to baseline levels by EOT.", "labels": [], "entities": []}, {"text": "Similarly,  nicotine withdrawal scores increased at the TQD time point but returned to prequit levels by EOT, F(6, 73.6)511.52, p,0.0001.", "labels": [], "entities": []}, {"text": "Weight during treatment was stable with no effects for medication, therapy, time, or their interactions.", "labels": [], "entities": []}, {"text": "Composite side effect scores were similar for both bupropion and placebo groups with no differences as a function of medication, therapy, time, or their interactions.", "labels": [], "entities": []}, {"text": "In this gender-specific study of bupropion, concurrent intensive therapy, and medication compliance, we observed the following: (a) response to bupropion varied as a function of therapy, in the direction of improved abstinence rates when the medication was delivered concurrently with CBT, (b) the bupropion-CBT combination was not clearly superior to placebo, regardless of therapy assignment, (c) as predicted, higher rates of medication compliance were positively predictive of abstinence, and this effect was most evident in the placebo condition.", "labels": [], "entities": []}, {"text": "Explanations for these findings are presented below, along with study strengths and weaknesses that must be considered in drawing conclusions from this preliminary evaluation.", "labels": [], "entities": []}, {"text": "It has been suggested that intensive behavioral counseling is more influential in women than men (e.g.,).", "labels": [], "entities": []}, {"text": "The present study is among the first to examine differences in specific types of intensive smoking cessation therapies when delivered in conjunction with pharmacotherapy.", "labels": [], "entities": []}, {"text": "We hypothesized that coping skills training via CBT would equip smokers with strategies for managing stress, negative affect, and lapses, all of which appear to present special challenges to women smokers).", "labels": [], "entities": []}, {"text": "That this form of therapy appeared to improve cessation rates in women receiving bupropion is consistent with our hypothesis but not easy to interpret in the context of cessation rates observed in women receiving placebo, who tended to do worse with CBT.", "labels": [], "entities": []}, {"text": "The reason for this finding, and its validity, is unclear.", "labels": [], "entities": []}, {"text": "It maybe that CBT, with its focus on identifying smoking-related situations, elicited cue-induced craving that was overcome by bupropion but not placebo.", "labels": [], "entities": []}, {"text": "This possible mechanism, while intriguing, awaits future research involving more direct measures of cue reactivity and craving.", "labels": [], "entities": []}, {"text": "Considering the higher-than-expected overall placebo cessation rate, we are cautious to avoid overinterpretation of the bupropion-CBT combination.", "labels": [], "entities": []}, {"text": "Previously, in a nonmedication smoking cessation study of intensive therapies for women, CBT was found to be as effective as therapy based on the health belief model of behavior change ().", "labels": [], "entities": []}, {"text": "In the broader substance abuse treatment literature, CBT has failed to show consistent superiority over other active psychotherapies).", "labels": [], "entities": []}, {"text": "Whereas CBT is clearly distinguishable in content and delivery from other forms of therapy (shown here in), the mechanisms underlying behavior change associated with CBT and alternative therapies may not be different.", "labels": [], "entities": []}, {"text": "Thus, in the absence of stronger supporting evidence, our findings favor guideline-recommended strategies of coping skills training and supportive counseling in treating tobacco use and dependence ().", "labels": [], "entities": []}, {"text": "Meta-analytic results of the effects of bupropion treatment on cessation outcomes demonstrate that women are more likely to quit smoking with bupropion than with placebo (.", "labels": [], "entities": []}, {"text": "Although our failure to detect a medication main effect is not consistent with these summative conclusions, the present study can be added to Scharf and Shiffman's list of randomized clinical trials in which the bupropion-placebo difference was not significant when evaluated separately in the subgroup of female smokers ().", "labels": [], "entities": []}, {"text": "In the, average EOT cessation outcomes across 12 randomized clinical trials were 18% and 34% in women treated with placebo and bupropion, respectively.", "labels": [], "entities": []}, {"text": "In the present study, EOT cessation outcomes in the placebo and bupropion group were 27.5% and 31%, respectively.", "labels": [], "entities": []}, {"text": "Characteristics of our study design may account in part for the elevated placebo response.", "labels": [], "entities": []}, {"text": "Compared with the brief behavioral individual cessation counseling described inmost of the previously reported studies, here the intensity of the psychotherapy and its delivery to women in smallgroup format may have created a ceiling effect that restricted our ability to observe additional benefit from a second (medication) treatment.", "labels": [], "entities": []}, {"text": "In other smoking trials using active psychotherapies, the efficacy of added pharmacotherapy has been undetected or weakened (e.g., Covey, Glassman, Stetner,).", "labels": [], "entities": []}, {"text": "Medication compliance and its positive relationship with clinical outcome is a robust finding that has been reported in studies across a range of prescribed medical and psychiatric treatments.", "labels": [], "entities": []}, {"text": "With smoking pharmacotherapies, however, the potential influence of medication compliance in treatment outcome has received relatively little attention.", "labels": [], "entities": []}, {"text": "Among the published bupropion clinical trials for smoking cessation, only a few have included information on amounts of medication used or compliance rates.", "labels": [], "entities": [{"text": "smoking", "start_pos": 50, "end_pos": 57, "type": "Smoking", "confidence": 0.7693854570388794}]}, {"text": "Recently, in a small open-label study of medication compliance enhancement with MEMSbased feedback, we showed that individuals with higher levels of compliance were more likely to be abstinent at 3 - and 6 - weeks postcessation).", "labels": [], "entities": []}, {"text": "The present study examined compliance level in relation to EOT outcome and failed to show its predictive utility in bupropion-treated women.", "labels": [], "entities": []}, {"text": "Given the overall low levels of medication compliance (Mdn544% doses taken) and low rate of treatment completion (57%) in this sample of women, it is possible that many participants failed to achieve and maintain a therapeutic dose of bupropion, which typically requires the recommended 7 - 12 weeks).", "labels": [], "entities": []}, {"text": "The extent to which adequate dosing of bupropion is problematic for women relative to men is unknown, but is worthy of further investigation.", "labels": [], "entities": []}, {"text": "Better compliance seemed to strengthen the placebo effect, supporting the general notion that placebo ''works'' better in more compliant people (e.g.,).", "labels": [], "entities": []}, {"text": "Taken together, the pattern of results from the present study suggests a link between compliance and smoking outcome in women.", "labels": [], "entities": []}, {"text": "The extent to which this association is mediated by the specific ''biological'' effects of pharmacotherapy remains uncertain.", "labels": [], "entities": []}, {"text": "The group format used in the present study, irrespective of therapy type, may have provided a source of social support and cohesion that women in particular find beneficial for smoking cessation).", "labels": [], "entities": []}, {"text": "This study focused primarily on outcomes, however, not on group processes or dynamics.", "labels": [], "entities": []}, {"text": "Our data analytic approach controlled for group membership statistically but did not fully address the problems associated with the between-group heterogeneity or within-group homogeneity that can arise in small groups.", "labels": [], "entities": []}, {"text": "To the extent that our groups varied in level of cohesion, this factor may have influenced therapy attendance and smoking behavior, as others have documented).", "labels": [], "entities": []}, {"text": "Measures were taken to prevent systematic differences between groups, including delivery of treatment by the same therapist pairs, restricting group size (4 - 8 members), using therapy manuals, and applying stringent adherence checks.", "labels": [], "entities": []}, {"text": "Nevertheless, the present results may not generalize to smoking cessation therapy studies in which treatment is delivered in individual format.", "labels": [], "entities": [{"text": "smoking", "start_pos": 56, "end_pos": 63, "type": "Smoking", "confidence": 0.7394181489944458}]}, {"text": "In fact, whether the characteristics of women smokers who participate in clinical trials are representative of the general population of women smokers is unknown.", "labels": [], "entities": []}, {"text": "Our findings are viewed as preliminary in light of important study limitations.", "labels": [], "entities": []}, {"text": "The small sample size and low follow-up rates most likely explain the failure to demonstrate clear advantage of any treatment condition, independently or combined.", "labels": [], "entities": []}, {"text": "The assessment of medication taking using MEMS may have introduced a third, unintended and nonspecific element of treatment, further obscuring true treatment effects.", "labels": [], "entities": []}, {"text": "However, given the influence of medication compliance on outcomes in the present study, we hope that greater attention is paid to this methodological variable in future clinical trial research.", "labels": [], "entities": []}, {"text": "Finally, as mentioned earlier, results from the present sample of smokers, recruited into a women-only trial of medication and group-based therapy, may not generalize to other populations or treatment settings.", "labels": [], "entities": []}, {"text": "Obviously, without a male sample for comparison, we cannot conclude that the present findings are unique to women.", "labels": [], "entities": []}, {"text": "These limitations notwithstanding, the present study addresses the important goal of improving smoking cessation interventions for women.", "labels": [], "entities": []}, {"text": "In addition to the call for more research on gender differences in outcomes of clinical trials involving medications or behavioral therapies), the present study illustrates the need for further investigation of heterogeneity in treatment outcomes among women in general.", "labels": [], "entities": []}, {"text": "The notion of uniformity in outcome following use of bupropion with concurrent psychotherapy may not hold true for women.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: White: 25 of Placebo: Supportive: therapy n537: Number of: Percent has a value of 67.6.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: White: 25: 27 of Placebo: Cognitive-behavioral: therapy n539: Number of: Percent has a value of 69.2.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: White: 25: 27: 26 of Bupropion: Supportive: therapy n537: Number of: Percent has a value of 70.3.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: White: 25: 27: 26: 73: 30 of Bupropion: Cognitive-behavioral: therapy n541: Number of: Percent has a value of 73.2.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Black: 9 of Placebo: Supportive: therapy n537: Number of: Percent has a value of 24.3.", "labels": [], "entities": [{"text": "24.3", "start_pos": 110, "end_pos": 114, "type": "Mean_number_of_times_tobacco_used", "confidence": 0.4174154996871948}]}, {"text": "The Previous quit attemptsa: Black: 9: 10 of Placebo: Cognitive-behavioral: therapy n539: Number of: Percent has a value of 25.7.", "labels": [], "entities": [{"text": "25.7", "start_pos": 124, "end_pos": 128, "type": "Mean_number_of_times_tobacco_used", "confidence": 0.4778098165988922}]}, {"text": "The Previous quit attemptsa: Black: 9: 10: 10 of Bupropion: Supportive: therapy n537: Number of: Percent has a value of 27.0.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Black: 9: 10: 10: 73: 10 of Bupropion: Cognitive-behavioral: therapy n541: Number of: Percent has a value of 24.4.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Hispanic: 3 of Placebo: Supportive: therapy n537: Number of: Percent has a value of 8.1.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Hispanic: 3: 2 of Placebo: Cognitive-behavioral: therapy n539: Number of: Percent has a value of 5.1.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Hispanic: 3: 2: 1 of Bupropion: Supportive: therapy n537: Number of: Percent has a value of 2.7.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Hispanic: 3: 2: 1: 73: 1 of Bupropion: Cognitive-behavioral: therapy n541: Number of: Percent has a value of 2.4.", "labels": [], "entities": []}, {"text": "The Married: Previous quit attemptsa: 12 of Placebo: Supportive: therapy n537: Number of: Percent has a value of 32.4.", "labels": [], "entities": []}, {"text": "The Married: Previous quit attemptsa: 12: 18 of Placebo: Cognitive-behavioral: therapy n539: Number of: Percent has a value of 46.2.", "labels": [], "entities": []}, {"text": "The Married: Previous quit attemptsa: 12: 18: 13 of Bupropion: Supportive: therapy n537: Number of: Percent has a value of 35.1.", "labels": [], "entities": []}, {"text": "The Married: Previous quit attemptsa: 12: 18: 13: 73: 19 of Bupropion: Cognitive-behavioral: therapy n541: Number of: Percent has a value of 46.3.", "labels": [], "entities": []}, {"text": "The Employed: Previous quit attemptsa: 25 of Placebo: Supportive: therapy n537: Number of: Percent has a value of 67.6.", "labels": [], "entities": []}, {"text": "The Employed: Previous quit attemptsa: 25: 21 of Placebo: Cognitive-behavioral: therapy n539: Number of: Percent has a value of 53.8.", "labels": [], "entities": []}, {"text": "The Employed: Previous quit attemptsa: 25: 21: 27: 73: 27 of Bupropion: Cognitive-behavioral: therapy n541: Number of: Percent has a value of 65.9.", "labels": [], "entities": []}, {"text": "The Smokers in home: Previous quit attemptsa: 10: 27: 13 of Placebo: Cognitive-behavioral: therapy n539: Number of: Percent has a value of 33.3.", "labels": [], "entities": []}, {"text": "The Smokers in home: Previous quit attemptsa: 10: 27: 13: 10: 27: 13 of Bupropion: Cognitive-behavioral: therapy n541: Number of: Percent has a value of 31.7.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa of Placebo: Supportive: therapy n537: Number of: subjects: Mean has a value of 47.7.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: 10 of Placebo: Supportive: therapy n537: Number of: Percent: SD has a value of 9.1.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: 10: 50 of Placebo: Cognitive-behavioral: therapy n539: Number of: Percent: SD has a value of 9.4.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: 10: 50: 47 of Bupropion: Supportive: therapy n537: Number of: Percent: SD has a value of 9.2.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: 10: 50: 47: 2 of Bupropion: Cognitive-behavioral: therapy n541: Number of: subjects: Mean has a value of 46.5.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: 10: 50: 47: 2: 13 of Bupropion: Cognitive-behavioral: therapy n541: Number of: Percent: SD has a value of 9.5.", "labels": [], "entities": []}, {"text": "The Education (years) of Placebo: Supportive: therapy n537: Number of: subjects: Mean has a value of 14.5.", "labels": [], "entities": []}, {"text": "The Education (years): 10 of Placebo: Supportive: therapy n537: Number of: Percent: SD has a value of 2.2.", "labels": [], "entities": []}, {"text": "The Education (years): 10 of Placebo: Cognitive-behavioral: therapy n539: Number of: subjects: Mean has a value of 14.1.", "labels": [], "entities": []}, {"text": "The Education (years): 10: 31 of Placebo: Cognitive-behavioral: therapy n539: Number of: Percent: SD has a value of 2.9.", "labels": [], "entities": []}, {"text": "The Education (years): 10: 50 of Bupropion: Supportive: therapy n537: Number of: subjects: Mean has a value of 14.4.", "labels": [], "entities": []}, {"text": "The Education (years): 10: 50: 47: 2 of Bupropion: Cognitive-behavioral: therapy n541: Number of: subjects: Mean has a value of 14.1.", "labels": [], "entities": []}, {"text": "The Education (years): 10: 50: 47: 2: 13 of Bupropion: Cognitive-behavioral: therapy n541: Number of: Percent: SD has a value of 2.6.", "labels": [], "entities": []}, {"text": "The Years smoked of Placebo: Supportive: therapy n537: Number of: subjects: Mean has a value of 27.7.", "labels": [], "entities": [{"text": "27.7", "start_pos": 96, "end_pos": 100, "type": "Mean_number_of_times_tobacco_used", "confidence": 0.45280003547668457}]}, {"text": "The Years smoked: 10 of Placebo: Supportive: therapy n537: Number of: Percent: SD has a value of 9.9.", "labels": [], "entities": []}, {"text": "The Years smoked: 10: 31 of Placebo: Cognitive-behavioral: therapy n539: Number of: Percent: SD has a value of 10.8.", "labels": [], "entities": []}, {"text": "The Years smoked: 10: 31 of Bupropion: Supportive: therapy n537: Number of: subjects: Mean has a value of 27.4.", "labels": [], "entities": [{"text": "27.4", "start_pos": 106, "end_pos": 110, "type": "Mean_number_of_times_tobacco_used", "confidence": 0.5855327844619751}]}, {"text": "The Years smoked: 10: 31: 47 of Bupropion: Supportive: therapy n537: Number of: Percent: SD has a value of 11.2.", "labels": [], "entities": []}, {"text": "The Years smoked: 10: 31: 47: 2 of Bupropion: Cognitive-behavioral: therapy n541: Number of: subjects: Mean has a value of 27.9.", "labels": [], "entities": [{"text": "27.9", "start_pos": 123, "end_pos": 127, "type": "Mean_number_of_times_tobacco_used", "confidence": 0.6037746071815491}]}, {"text": "The Years smoked: 10: 31: 47: 2: 13 of Bupropion: Cognitive-behavioral: therapy n541: Number of: Percent: SD has a value of 10.6.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa of Placebo: Supportive: therapy n537: Number of: subjects: Mean has a value of 3.4.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: 10 of Placebo: Cognitive-behavioral: therapy n539: Number of: subjects: Mean has a value of 3.2.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: 10: 31 of Bupropion: Supportive: therapy n537: Number of: subjects: Mean has a value of 3.7.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: 10: 31: 47: 2 of Bupropion: Cognitive-behavioral: therapy n541: Number of: subjects: Mean has a value of 3.2.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Longest quit (days) of Placebo: Supportive: therapy n537: Number of: subjects: Mean has a value of 38.9.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Longest quit (days): 158 of Placebo: Cognitive-behavioral: therapy n539: Number of: subjects: Mean has a value of 25.5.", "labels": [], "entities": [{"text": "25.5", "start_pos": 143, "end_pos": 147, "type": "Mean_number_of_times_tobacco_used", "confidence": 0.5052490830421448}]}, {"text": "The Previous quit attemptsa: Longest quit (days): 158: 20 of Bupropion: Supportive: therapy n537: Number of: subjects: Mean has a value of 23.9.", "labels": [], "entities": [{"text": "23.9", "start_pos": 139, "end_pos": 143, "type": "Mean_number_of_times_tobacco_used", "confidence": 0.44100698828697205}]}, {"text": "The Previous quit attemptsa: Longest quit (days): 158: 20: 47: 2 of Bupropion: Cognitive-behavioral: therapy n541: Number of: subjects: Mean has a value of 36.4.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Cigarettes/day of Placebo: Supportive: therapy n537: Number of: subjects: Mean has a value of 20.2.", "labels": [], "entities": [{"text": "20.2", "start_pos": 123, "end_pos": 127, "type": "Mean_number_of_times_tobacco_used", "confidence": 0.7797898650169373}]}, {"text": "The Previous quit attemptsa: Cigarettes/day: 158 of Placebo: Supportive: therapy n537: Number of: Percent: SD has a value of 8.9.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Cigarettes/day: 158: 20 of Placebo: Cognitive-behavioral: therapy n539: Number of: Percent: SD has a value of 9.1.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Cigarettes/day: 158: 20 of Bupropion: Supportive: therapy n537: Number of: subjects: Mean has a value of 21.1.", "labels": [], "entities": [{"text": "21.1", "start_pos": 134, "end_pos": 138, "type": "Mean_number_of_times_tobacco_used", "confidence": 0.6655974388122559}]}, {"text": "The Previous quit attemptsa: Cigarettes/day: 158: 20: 47 of Bupropion: Supportive: therapy n537: Number of: Percent: SD has a value of 8.4.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Cigarettes/day: 158: 20: 47: 10 of Bupropion: Cognitive-behavioral: therapy n541: Number of: subjects: Mean has a value of 24.6.", "labels": [], "entities": [{"text": "24.6", "start_pos": 152, "end_pos": 156, "type": "Mean_number_of_times_tobacco_used", "confidence": 0.6530964970588684}]}, {"text": "The Previous quit attemptsa: Cigarettes/day: 158: 20: 47: 10: 13 of Bupropion: Cognitive-behavioral: therapy n541: Number of: Percent: SD has a value of 10.5.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: FTND score of Placebo: Supportive: therapy n537: Number of: subjects: Mean has a value of 5.5.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: FTND score: 158 of Placebo: Supportive: therapy n537: Number of: Percent: SD has a value of 2.5.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: FTND score: 158 of Placebo: Cognitive-behavioral: therapy n539: Number of: subjects: Mean has a value of 5.1.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: FTND score: 158: 20 of Placebo: Cognitive-behavioral: therapy n539: Number of: Percent: SD has a value of 2.2.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: FTND score: 158: 20 of Bupropion: Supportive: therapy n537: Number of: subjects: Mean has a value of 6.1.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: FTND score: 158: 20: 47 of Bupropion: Supportive: therapy n537: Number of: Percent: SD has a value of 2.3.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: FTND score: 158: 20: 47: 10 of Bupropion: Cognitive-behavioral: therapy n541: Number of: subjects: Mean has a value of 6.2.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: FTND score: 158: 20: 47: 10: 13 of Bupropion: Cognitive-behavioral: therapy n541: Number of: Percent: SD has a value of 2.1.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Carbon monoxide of Placebo: Supportive: therapy n537: Number of: subjects: Mean has a value of 22.6.", "labels": [], "entities": [{"text": "22.6", "start_pos": 124, "end_pos": 128, "type": "Mean_number_of_times_tobacco_used", "confidence": 0.5875904560089111}]}, {"text": "The Previous quit attemptsa: Carbon monoxide: 158 of Placebo: Supportive: therapy n537: Number of: Percent: SD has a value of 12.9.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Carbon monoxide: 158 of Placebo: Cognitive-behavioral: therapy n539: Number of: subjects: Mean has a value of 23.7.", "labels": [], "entities": [{"text": "23.7", "start_pos": 139, "end_pos": 143, "type": "Mean_number_of_times_tobacco_used", "confidence": 0.6017141938209534}]}, {"text": "The Previous quit attemptsa: Carbon monoxide: 158: 20 of Placebo: Cognitive-behavioral: therapy n539: Number of: Percent: SD has a value of 13.8.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Carbon monoxide: 158: 20 of Bupropion: Supportive: therapy n537: Number of: subjects: Mean has a value of 22.5.", "labels": [], "entities": [{"text": "22.5", "start_pos": 135, "end_pos": 139, "type": "Mean_number_of_times_tobacco_used", "confidence": 0.5421934127807617}]}, {"text": "The Previous quit attemptsa: Carbon monoxide: 158: 20: 47: 10 of Bupropion: Cognitive-behavioral: therapy n541: Number of: subjects: Mean has a value of 23.6.", "labels": [], "entities": [{"text": "23.6", "start_pos": 153, "end_pos": 157, "type": "Mean_number_of_times_tobacco_used", "confidence": 0.5869495868682861}]}, {"text": "The Previous quit attemptsa: Carbon monoxide: 158: 20: 47: 10: 13 of Bupropion: Cognitive-behavioral: therapy n541: Number of: Percent: SD has a value of 10.9.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Cotinine (ng/ml) of Placebo: Supportive: therapy n537: Number of: subjects: Mean has a value of 237.2.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Cotinine (ng/ml): 158 of Placebo: Cognitive-behavioral: therapy n539: Number of: subjects: Mean has a value of 256.3.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Cotinine (ng/ml): 158: 20 of Bupropion: Supportive: therapy n537: Number of: subjects: Mean has a value of 270.3.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Cotinine (ng/ml): 158: 20: 47: 41 of Bupropion: Cognitive-behavioral: therapy n541: Number of: subjects: Mean has a value of 242.8.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Weight (pounds): 158 of Placebo: Supportive: therapy n537: Number of: Percent: SD has a value of 32.1.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Weight (pounds): 158 of Placebo: Cognitive-behavioral: therapy n539: Number of: subjects: Mean has a value of 155.7.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Weight (pounds): 158: 20 of Placebo: Cognitive-behavioral: therapy n539: Number of: Percent: SD has a value of 37.5.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Weight (pounds): 158: 20 of Bupropion: Supportive: therapy n537: Number of: subjects: Mean has a value of 160.9.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Weight (pounds): 158: 20: 47: 41 of Bupropion: Cognitive-behavioral: therapy n541: Number of: subjects: Mean has a value of 175.9.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: Weight (pounds): 158: 20: 47: 41: 13 of Bupropion: Cognitive-behavioral: therapy n541: Number of: Percent: SD has a value of 48.6.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: BDI score of Placebo: Supportive: therapy n537: Number of: subjects: Mean has a value of 6.8.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: BDI score: 158 of Placebo: Supportive: therapy n537: Number of: Percent: SD has a value of 5.2.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: BDI score: 158 of Placebo: Cognitive-behavioral: therapy n539: Number of: subjects: Mean has a value of 7.9.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: BDI score: 158: 20 of Placebo: Cognitive-behavioral: therapy n539: Number of: Percent: SD has a value of 6.7.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: BDI score: 158: 20 of Bupropion: Supportive: therapy n537: Number of: subjects: Mean has a value of 6.7.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: BDI score: 158: 20: 47 of Bupropion: Supportive: therapy n537: Number of: Percent: SD has a value of 5.9.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: BDI score: 158: 20: 47: 41 of Bupropion: Cognitive-behavioral: therapy n541: Number of: subjects: Mean has a value of 7.2.", "labels": [], "entities": []}, {"text": "The Previous quit attemptsa: BDI score: 158: 20: 47: 41: 13 of Bupropion: Cognitive-behavioral: therapy n541: Number of: Percent: SD has a value of 6.4.", "labels": [], "entities": []}]